The agency seeks comments through Nov. 8 on an external request to expand Medicare coverage for positron emission tomography (PET) tracers to agents that image beta-amyloid plaques to diagnose dementia and other neurogenerative diseases. CMS opened the national coverage analysis Oct. 9 in response to a June 29 letter from Eli Lilly & Co.
Reimbursement In Brief
CMS opens national coverage analysis for PET tracers to diagnose dementia. HHS Office of Inspector General reports on prosthetics and orthotics payments. More reimbursement news.